AVAX Technologies, Inc. Stock Other OTC
Equities
AVXT
US0534953056
Biotechnology & Medical Research
Financials (USD)
Sales 2009 | 399K | Sales 2010 | 142K | Capitalization | 6.29M |
---|---|---|---|---|---|
Net income 2009 | -19M | Net income 2010 | -12M | EV / Sales 2009 | 69 x |
Net Debt 2009 | 3.23M | Net Debt 2010 | 3.1M | EV / Sales 2010 | 65.9 x |
P/E ratio 2009 |
-1.24
x | P/E ratio 2010 |
-1.03
x | Employees | - |
Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Adele Sommerfeld
CEO | Chief Executive Officer | - | 15-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew W. Dahl
CHM | Chairman | 79 | 99-08-31 |
Adele Sommerfeld
CEO | Chief Executive Officer | - | 15-10-18 |
Bruno Maruzzo
BRD | Director/Board Member | 71 | - |
1st Jan change | Capi. | |
---|---|---|
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |